These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
230 related articles for article (PubMed ID: 29858682)
1. Survival analysis and pathological features of advanced non-small cell lung cancer with miliary pulmonary metastases in patients harboring epidermal growth factor receptor mutations. Okuma Y; Kashima J; Watanabe K; Homma S J Cancer Res Clin Oncol; 2018 Aug; 144(8):1601-1611. PubMed ID: 29858682 [TBL] [Abstract][Full Text] [Related]
2. Efficacy of EGFR tyrosine kinase inhibitors in non-small cell lung cancer patients harboring different types of EGFR mutations: A retrospective analysis. Liu HL; Han G; Peng M; Weng YM; Yuan JP; Yang GF; Yu JM; Song QB J Huazhong Univ Sci Technolog Med Sci; 2017 Dec; 37(6):864-872. PubMed ID: 29270745 [TBL] [Abstract][Full Text] [Related]
3. Expression of insulin-like growth factor 1 receptor (IGF-1R) predicts poor responses to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in non-small cell lung cancer patients harboring activating EGFR mutations. Yeo CD; Park KH; Park CK; Lee SH; Kim SJ; Yoon HK; Lee YS; Lee EJ; Lee KY; Kim TJ Lung Cancer; 2015 Mar; 87(3):311-7. PubMed ID: 25617986 [TBL] [Abstract][Full Text] [Related]
4. The association between clinical prognostic factors and epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) efficacy in advanced non-small-cell lung cancer patients: a retrospective assessment of 94 cases with EGFR mutations. Lin JH; Lin D; Xu L; Wang Q; Hu HH; Xu HP; He ZY Oncotarget; 2017 Jan; 8(2):3412-3421. PubMed ID: 27926500 [TBL] [Abstract][Full Text] [Related]
5. EGFR tyrosine kinase inhibitor (TKI) in patients with advanced non-small cell lung cancer (NSCLC) harboring uncommon EGFR mutations: A real-world study in China. Xu J; Jin B; Chu T; Dong X; Yang H; Zhang Y; Wu D; Lou Y; Zhang X; Wang H; Han B Lung Cancer; 2016 Jun; 96():87-92. PubMed ID: 27133756 [TBL] [Abstract][Full Text] [Related]
6. Cytokeratin 19 fragment predicts the efficacy of epidermal growth factor receptor-tyrosine kinase inhibitor in non-small-cell lung cancer harboring EGFR mutation. Tanaka K; Hata A; Kaji R; Fujita S; Otoshi T; Fujimoto D; Kawamura T; Tamai K; Takeshita J; Matsumoto T; Monden K; Nagata K; Otsuka K; Nakagawa A; Tachikawa R; Otsuka K; Tomii K; Katakami N J Thorac Oncol; 2013 Jul; 8(7):892-8. PubMed ID: 23591159 [TBL] [Abstract][Full Text] [Related]
7. Advanced non-Small cell lung cancer patients at the extremes of age in the era of epidermal growth factor receptor tyrosine kinase inhibitors. Chen YM; Lai CH; Rau KM; Huang CH; Chang HC; Chao TY; Tseng CC; Fang WF; Chen YC; Chung YH; Wang YH; Su MC; Huang KT; Liu SF; Chen HC; Chang YC; Chang YP; Wang CC; Lin MC Lung Cancer; 2016 Aug; 98():99-105. PubMed ID: 27393514 [TBL] [Abstract][Full Text] [Related]
8. RECIST progression patterns during EGFR tyrosine kinase inhibitor treatment of advanced non-small cell lung cancer patients harboring an EGFR mutation. Yoshida T; Yoh K; Niho S; Umemura S; Matsumoto S; Ohmatsu H; Ohe Y; Goto K Lung Cancer; 2015 Dec; 90(3):477-83. PubMed ID: 26604031 [TBL] [Abstract][Full Text] [Related]
9. Effects of epidermal growth factor receptor-tyrosine kinase inhibitors alone on EGFR-mutant non-small cell lung cancer with brain metastasis. Zhang Q; Zhang X; Yan H; Jiang B; Xu C; Yang J; Chen Z; Su J; Wu YL; Zhou Q Thorac Cancer; 2016 Nov; 7(6):648-654. PubMed ID: 27755835 [TBL] [Abstract][Full Text] [Related]
10. The impact of clinical parameters on progression-free survival of non-small cell lung cancer patients harboring EGFR-mutations receiving first-line EGFR-tyrosine kinase inhibitors. Chen YM; Lai CH; Chang HC; Chao TY; Tseng CC; Fang WF; Wang CC; Chung YH; Wang YH; Su MC; Huang KT; Chen HC; Lin MC Lung Cancer; 2016 Mar; 93():47-54. PubMed ID: 26898614 [TBL] [Abstract][Full Text] [Related]
11. Is there any predictor for clinical outcome in EGFR mutant NSCLC patients treated with EGFR TKIs? Lee JY; Lim SH; Kim M; Kim S; Jung HA; Chang WJ; Choi MK; Hong JY; Lee SJ; Sun JM; Ahn JS; Park K; Ahn MJ Cancer Chemother Pharmacol; 2014 May; 73(5):1063-70. PubMed ID: 24663503 [TBL] [Abstract][Full Text] [Related]
12. Prolonged survival of patients with EGFR-mutated non-small cell lung cancer with solitary brain metastases treated with surgical resection of brain and lung lesions followed by EGFR TKIs. Gui Q; Liu J; Li D; Xu C World J Surg Oncol; 2017 Oct; 15(1):184. PubMed ID: 29037198 [TBL] [Abstract][Full Text] [Related]
13. Impact of systematic EGFR and KRAS mutation evaluation on progression-free survival and overall survival in patients with advanced non-small-cell lung cancer treated by erlotinib in a French prospective cohort (ERMETIC project--part 2). Cadranel J; Mauguen A; Faller M; Zalcman G; Buisine MP; Westeel V; Longchampt E; Wislez M; Coudert B; Daniel C; Chetaille B; Michiels S; Blons H; Solassol J; De Fraipont F; Foucher P; Urban T; Lacroix L; Poulot V; Quoix E; Antoine M; Danton G; Morin F; Chouaid C; Pignon JP J Thorac Oncol; 2012 Oct; 7(10):1490-502. PubMed ID: 22982650 [TBL] [Abstract][Full Text] [Related]
14. Comparison of clinical outcomes following gefitinib and erlotinib treatment in non-small-cell lung cancer patients harboring an epidermal growth factor receptor mutation in either exon 19 or 21. Lim SH; Lee JY; Sun JM; Ahn JS; Park K; Ahn MJ J Thorac Oncol; 2014 Apr; 9(4):506-11. PubMed ID: 24736073 [TBL] [Abstract][Full Text] [Related]
15. Cytotoxic chemotherapy may overcome the development of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) therapy. Kanda S; Horinouchi H; Fujiwara Y; Nokihara H; Yamamoto N; Sekine I; Kunitoh H; Kubota K; Tamura T; Ohe Y Lung Cancer; 2015 Sep; 89(3):287-93. PubMed ID: 26169499 [TBL] [Abstract][Full Text] [Related]
16. Local Therapy for Oligoprogressive Disease in Patients With Advanced Stage Non-small-cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutation. Qiu B; Liang Y; Li Q; Liu G; Wang F; Chen Z; Liu M; Zhao M; Liu H Clin Lung Cancer; 2017 Nov; 18(6):e369-e373. PubMed ID: 28465010 [TBL] [Abstract][Full Text] [Related]
17. Clinical Impact of Post-Progression Survival on Overall Survival in Elderly Patients with Non-Small-Cell Lung Cancer Harboring Sensitive EGFR Mutations Treated with First-Line EGFR Tyrosine Kinase Inhibitors. Imai H; Yamada Y; Sugiyama T; Minemura H; Kaira K; Kanazawa K; Kasai T; Kaburagi T; Minato K; Chemotherapy; 2018; 63(3):181-189. PubMed ID: 30107372 [TBL] [Abstract][Full Text] [Related]
18. The Efficacy of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer Harboring Wild-type Epidermal Growth Factor Receptor: A Meta-analysis of 25 RCTs. Sheng Z; Zhang Y Am J Clin Oncol; 2017 Aug; 40(4):362-369. PubMed ID: 25647830 [TBL] [Abstract][Full Text] [Related]
19. [Serum CYFRA21-1 is Correlated with the Efficacy of Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitor in Non-small Cell Lung Cancer Patients Harboring EGFR Mutations]. Wang Q; Zheng H; Hu F; Zhang H; Hu Y; Li J; Zhang T; Liu Z; Lu B; Hu A; Li B Zhongguo Fei Ai Za Zhi; 2016 Aug; 19(8):550-8. PubMed ID: 27561807 [TBL] [Abstract][Full Text] [Related]
20. Distinct Benefit of Overall Survival between Patients with Non-Small-Cell Lung Cancer Harboring EGFR Exon 19 Deletion and Exon 21 L858R Substitution. Koyama N; Watanabe Y; Iwai Y; Kawamura R; Miwa C; Nagai Y; Hagiwara K; Koyama S Chemotherapy; 2017; 62(3):151-158. PubMed ID: 28110331 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]